This tool allows the prediction of tumor control for early-stage lung cancer for different fractionation sizes and schedules. It is based on work by Jeong et al which showed that a mechanistic mathematical model can quantitatively predict the tremendous differences in response seen in early-stage lung cancer across the range of clinical dose and fractionation schemes. The model can be used to predict which fractionation schemes over- or undertreat lung tumors.